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abusers were 1.5-fold as likely to have medically related absen-
teeism days, and 8.5 times as likely to have a disability claim
compared to controls (p < 0.01). Opioid abusers had higher
average annual medically related absenteeism days compared to
controls (26.4 days vs. 5.7 days, p < 0.01). Mean annual direct
health care costs for opioid abusers were over eight times higher
than controls ($15,884 vs. $1830, p < 0.01). Hospital inpatient
and doctor/outpatient costs accounted for 46% ($7239) and
31% ($5000) of opioid abusers’ health care costs, versus 17%
($310) and 50% ($906), respectively, for controls. Mean annual
indirect workloss costs for opioid abusers were over eight times
higher than controls ($4167 vs. $502, p < 0.01). CONCLU-
SIONS: These high costs were driven partly by high utilization
rates of medical services and prescription drugs, and higher
prevalence of workloss. Our estimates may be conservative as
only patients diagnosed with abuse were included. To the extent
that the abuse is prescription opioid abuse, payers should ensure
appropriate access to opioids while considering abuse liability of
drugs on formulary.
(For abstract PMH2 see page 256) MH2
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OBJECTIVES: To examine use, timing and cost of Emergency
Department (ED) visits by those of college age (17–22 years) for
acute alcohol intoxication. METHODS: Cases were identiﬁed
from Massachusetts 2002 ED and hospital databases using ICD-
9 principal diagnosis codes 305.00–305.09. Hospital cases were
limited to those admitted via ED. Cost estimates include facility,
accommodations and ancillary services, reported in 2002 USD.
Charges were adjusted using a 0.55 cost-to-charge ratio.
RESULTS: Of 1803 cases identiﬁed, 52% were male and 55%
were less than 20-years old. Ambulances were used to transport
54%; law enforcement was involved in 1.5% of cases. The
majority (69%) arrived between 10:00 PM and 4:00 AM, and
70% of all visits occurred Friday through Sunday. Signiﬁcantly
(p = 0.004) more visits occurred in September and October than
any other month. The majority (94%) were treated and released
from ED, 1% was hospitalized, 2% eloped or left AMA, 2%
were transferred and 1% was recorded as unknown. Mean dura-
tion of ED visit was 5.4 hours (median: 4). Mean cost per ED
visit was $482 (median: $382) for those treated and released,
and $537 (median: $460) for those hospitalized. On average,
those admitted (n = 20) spent 2.5 days (median: 1) in the hos-
pital at a cost of $4540 (median: $2154). The cumulative hours
of ED time used in one year for treating alcohol intoxication in
this age group was 8254. Cumulative cost of ED and inpatient
care for the year was roughly $938,000. Managed care organi-
zations and commercial insurers were the responsible payers for
most cases (60%). Self-pay was noted for 24%. CONCLU-
SIONS: Acute alcohol intoxication among those of college age
results in a substantial direct medical cost, as well as an oppor-
tunity cost for ED resources during the year, particularly at the
start of the school year.
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OBJECTIVES: To determine quality-adjusted life-year (QALY)
gains associated with buprenorphine treatment for opiate addic-
tion, and estimate the potential cost savings of this treatment
from the societal perspective. METHODS: In a randomized 
clinical trial of buprenorphine therapy, subjects completed the
short-form-36 (SF-36) at baseline and every four weeks through
week-16, creating up to ﬁve data collection points for each
patient. We converted SF-36 data to SF-6D to calculate QALYs
for each patient-month through published techniques based
upon standard gamble methods. Dependent t-tests were used to
identify signiﬁcant differences in QALYs at baseline versus
QALYs at the end of each month. Our base case used a buprenor-
phine 12mg/day dosage plus annual buprenorphine treatment
clinic costs ($2356/person). We incorporated social costs of
untreated opiate addiction from the literature ($42,957/person-
year) and performed a sensitivity analysis using 8mg and 16mg
buprenorphine dosages. RESULTS: Due to dropouts, our sample
size was 100, 80, 69, 59, and 44 patients at baseline and months
one-four, respectively. QALY values (mean ± SD) for each month
were: 0.734 ± 0.091 at baseline, 0.761 ± 0.068 at month-one,
0.751 ± 0.087 at month-two, 0.754 ± 0.087 at month-three, and
0.757 ± 0.090 at month-four. Thus, an improvement of 0.027
QALYs (P = 0.008) between baseline and month-one occurred
(95% CI = 0.007–0.047). There were no other signiﬁcant
improvements, possibly due to patient dropouts. The sensitivity
analysis showed direct medical costs for buprenorphine treat-
ment ranged from $4206 to $6056 per person-year. By incorpo-
rating societal costs of untreated opiate addiction, a savings of
$36,901 to $38,752 per person-year was estimated. CONCLU-
SIONS: From a societal perspective, buprenorphine treatment
saves money and increases QALYs. For every 37 (95%CI =
21–143) patients treated there is a gain of one QALY. Wide-
spread adoption of proper ofﬁce-based buprenorphine treatment
is clearly indicated; undertreatment leads to exorbitant social
costs without QALY gains.
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OBJECTIVE: To estimate cost-effectiveness of Alprazolam
versus Clonazepam, Fluoxetine and Imipramine in anxiety dis-
orders in the Mexican Institute of Social Security (IMSS).
METHODS: A cost-effectiveness study was carried out with a
time horizon of one year, no discount rate was used. Utilization
of resources and effectiveness data were taken from an expert
panel of psychiatrists working at the IMSS and private sector.
Inclusion criteria for experts were: psychiatrists with more than
ﬁve years of clinical experience, that were certiﬁed by the
Mexican Council of Psychiatry and that had experience in using
the studied drugs in anxiety disorders. Use of resources included
hospitalisation, emergency services, visits, laboratory and diag-
nostic tests, as well as pocket expenses. Unit costs were taken
from Administrative and Financial departments of IMSS. Costs
were expressed in 2004 USD. Effectiveness measure was days
free of symptoms. Sensitivity analysis was univariate and prob-
abilistic. RESULTS: Annual treatment cost of anxiety disorders
with Alprazolam was $13,110, with Clonazepam $13,367, with
Fluoxetine $13,423 and with Imipramine $14,803. Effectiveness
results were 224 days without symptoms for Alprazolam, 232
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for Clonazepam and 181 for Fluoxetine and Imipramine. The
incremental cost-effectiveness analysis showed that the cost of an
extra unit of effectiveness was $32.2 when changing from Alpra-
zolam to Clonazepam, while the two other alternatives (Fluox-
etine and Imipramine) were dominated. Sensitivity analysis
conﬁrmed the direction and strength of our results. Conﬁdence
interval at 95% of the ICER was calculated by the ellipse method
and it showed that Alprazolam was dominant in 87% of the
cases. Acceptability curve described Alprazolam as the best
option with a willingness to pay threshold of $32.2. CONCLU-
SIONS: The best cost-effective alternative was Alprazolam fol-
lowed by Clonazepam. This results are relevant for the IMSS
because anxiety disorders cause work leaves and hospitalisa-
tions, and reduction in quality of life.
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OBJECTIVES: To assess the health and cost burdens of patients
with generalized anxiety disorder (GAD) and other anxiety dis-
orders, including their comorbidities, direct and indirect costs.
METHODS: The 1999–2003 MarketScan® claims databases of
over three million individuals (annually) were used to identify
patients with a diagnosis of GAD, other anxiety disorders (panic
disorder, phobias, post traumatic stress disorder, unspeciﬁed
anxiety state), and demographically-matched controls. Presence
of comorbidities, utilization, expenditures, absence and short-
term disability (STD) were summarized over a 12-month study
period. RESULTS: The prevalence of the following conditions
were signiﬁcantly (p < 0.001) higher among the 13,836 GAD
subjects and 31,882 other anxiety patients compared to the
89,971 controls: gastrointestinal disorders (19% GAD, 22%
other anxiety, 12% controls), genitourinary disorders (40%
GAD and other anxiety, 32% controls), cardiovascular disease
(10% GAD, 11% other anxiety, 7% controls), and chronic pain
(40% GAD, 44% other anxiety, 20% controls). Mean costs for
anxiety patients were twice as high as for controls ($6295 GAD,
$6800 other anxiety, $3156 controls, p < 0.001). These differ-
ences were driven by signiﬁcantly higher rates of ofﬁce visits and
prescription drug use among anxiety patients. Mental health
costs for GAD patients ($2031) or other anxiety patients ($2005)
did not account for all of the discrepancy. Among the subset of
patients with productivity data, anxiety patients had signiﬁcantly
higher indirect costs due to STD days ($2253 GAD, $3255 other
anxiety, $934 controls, p < 0.001). CONCLUSION: Patients
with GAD and other anxiety disorders have signiﬁcantly higher
costs compared to patients without these conditions. The direct
and indirect costs of anxiety result from mental health treatment
and treatments for physical comorbidities.
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DETERMINANTS OF PERMANENT NUSRING HOME
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Cai QC, Lin SJ
University of Illinois, Chicago, IL, USA
OBJECTIVES: To examine the determinants of time-to-
permanent nursing home admission among people aged 65 years
and over in the United States. METHODS: This study used data
from four waves of the Health Retirement Study (HRS) and
Assets and Health Dynamics among the Oldest Old surveys
(AHEAD) collected from 1995 to 2002. The dependent variable
was time-to-permanent nursing home admission, deﬁned as the
months from baseline survey in 1995 to the ﬁrst nursing home
stay of three or more months. Independent variables were mea-
sured at the baseline and included age, gender, race, education,
marital status, living arrangements, income, homeownership,
Medicaid, physical function (ADL/IADL), cognitive level, per-
ceived health status and certain chronic illnesses such as stroke,
psychiatric problems, fall and incontinence. RESULTS: In the
ﬁnal multivariable Cox model, older age (Hazard Ratio [HR],
1.11; 95% CI, 1.09–1.24), persons with psychiatric problems
(HR, 1.49; 95% CI, 1.19–1.87) and worse health were found 
to increase the risk of permanent nursing home admission
whereas being African American compared to white (HR, 0.85;
95% CI, 0.56–0.95) and persons with less cognitive impairment
(HR, 0.95; 95% CI, 0.91–0.99) had decreased risk. The inter-
action terms between time and living alone and IADL were 
signiﬁcant and less than one, which means the negative impacts
of living alone and worse IADL were decreasing over time.
Gender, education, marital status, income, homeownership,
Medicaid, ADL, stroke, fall and incontinence were not signiﬁ-
cant. CONCLUSION: Older age, psychiatric problems and
worse perceived health are the risk factors for permanent nursing
home admission. Living alone and worse IADL also increase the
risk of nursing home admission, however, the negative impacts
appear to ameliorate over time. The differential effects of ADL
and IADL on nursing home admission warrant more future
research.
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OBJECTIVES: This study assessed the effect of treatment with
venlafaxine extended release (XR), paroxetine and placebo on
health related work productivity among panic disorder patients.
METHODS: In a multicenter, double-blind trial, patients with
DSM-IV panic disorder were randomly assigned to ﬁxed-dose
(75mg/day or 225mg/day) venlafaxine XR, paroxetine 
(40mg/day), or placebo for a maximum of 12-weeks. Secondary
analyses focused on health-related work productivity impair-
ments as measured by the Work Limitations Questionnaire
(WLQ). WLQ has 25 items in four limitation dimensions (time,
physical, mental-interpersonal, and output demands). Treat-
ment-related improvements at ﬁnal-on-therapy (FOT) and week
12 were compared using analysis of covariance adjusting for
baseline impairment score and center. RESULTS: Venlafaxine
XR 225mg was associated with signiﬁcantly greater improve-
ment from baseline, relative to placebo, on all subscales of WLQ
(P < 0.005) except physical demands. At the FOT assessment,
venlafaxine XR 75mg showed signiﬁcant improvement com-
pared with placebo in time management (P < 0.05), marginally
signiﬁcant improvement in mental/interpersonal demands (P =
0.059) and output demands (P = 0.054), and no signiﬁcance 
for physical demands. Paroxetine failed to show signiﬁcant
improvement relative to placebo on all WLQ subscales in the
FOT assessment. CONCLUSION: Venlafaxine reduced work
impairment compared to placebo. Paroxetine did not separate
from placebo.
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